glp 1 drugs and pancreatitis Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy GLP-1 Agonists and Pancreatitis Risk

doi: 10.1111/dom.15083

The mechanism of action for weight reduction with metformin is not fully understood

Delivery methods other than injections and oral pills, such as sublingual drops and dissolving tablets, have not been tested in clinical trials

Pharmacokinetics and pharmacodynamiceffects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

With an increasing burden of diabetes and obesity, these drugs have the potential to reshape public health policies, redefine preventive care, and alter the economic landscape of the pharmaceutical industry

[DOI] [PMC free article] [PubMed] [Google Scholar] 34.Gimeno Orna JA, Ortez Toro JJ, Peteiro Miranda CM